Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Yakoub-Agha, I.; Chabannon, C.; Bader, P.; Basak, G.; Bonig, H.; Ciceri, F.; Corbacioglu, S.; Duarte, R.; Einsele, H.; Hudecek, M.; Kersten, M.; Köhl, U.; Kuball, J.; Mielke, S.; Mohty, M.; Murray, J.; Nagler, A.; Robinson, S.; Saccardi, R.; Sanchez-Guijo, F.; Snowden, J.; Srour, M.; Styczyński, J.; Urbano-Ispizua, Á.; Hayden, P.; Kröger, N.

doi:10.3324/haematol.2019.229781

Public

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Shared by NobleBlocks on Nov 21, 2019 • 12:00 AM UTC

Authors:

I. Yakoub-Agha

C. Chabannon

P. Bader

Abstract

Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leu...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!